Scarica l'app Stockscreener
2.93
0.34%
-0.010
Dopo l'orario di chiusura:
2.92
-0.01
-0.34%
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
CATX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Clinical ProgressForward Guidance Trends - newsline.com
Perspective Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Radioligand Therapy Market is Expected to Grow Rapidly by 2036, Estimates DelveInsight - openPR.com
Perspective Therapeutics (CATX) Institutional Ownership 2026 - MarketBeat
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial - Yahoo Finance
Perspective Therapeutics (CATX) Initiates Meningioma Patient Stu - GuruFocus
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - The Manila Times
Targeted alpha therapy trial doses first patient for common brain tumor - Stock Titan
Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort - Moomoo
Perspective Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer - The Globe and Mail
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities - The Globe and Mail
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline - TipRanks
Perspective updates corporate presentation detailing 212Pb radiopharmaceutical pipeline and regional production strategy - TradingView
Perspective Therapeutics (NYSE: CATX) outlines 212Pb cancer pipeline update - Stock Titan
Vivos Therapeutics (VVOS) Gains 4.5% as Stock Tests Key Resistance at $0.73Growth Stock Picks - thelegaladvocate.com
Edgewise Therapeutics Inc. (EWTW) Q1 2026 Earnings: Narrower Losses Bolster Investor SentimentRevenue Estimate Trend - thelegaladvocate.com
Cullinan Therapeutics (CGEM) Retreats 1% as Stock Approaches Support ZoneLarge Cap Trends - thelegaladvocate.com
Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting - Yahoo Finance
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEPS Surprise History - thelegaladvocate.com
Fluidra Appoints Juan Graham as Chief Financial Officer - hrtoday.in
Aprea Therapeutics (APRE) Edges Higher Amid Light Trading; Key Resistance at $0.99 in FocusOBV Divergence - thelegaladvocate.com
Perspective Therapeutics, Inc. 8-K Filing Details for May 27, 2026: Company Information and SEC Compliance - Minichart
Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026 - Yahoo Finance
Perspective Therapeutics shareholders approve directors and governance items - TipRanks
Shareholders of Perspective Therapeutics (NYSE: CATX) back board, auditor - Stock Titan
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: Loss Narrows Sharply, Stock Gains 2.84%Profitability Analysis - thelegaladvocate.com
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $8 to $15 - Moomoo
Perspective Therapeutics (CATX) Gains 2.84% as Stock Nears Key Resistance at $4.18High Yield Stocks - newsline.com
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: EPS Beat by 17% as Pre‑Revenue Biotech Advances Radiopharmaceutical PipelineEarnings Per Share - newsline.com
Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX) - The Globe and Mail
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6 - Moomoo
Piper Sandler Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Perspective Therapeutics Presents Positive Clinical Data for [212Pb] Radiopharmaceuticals in Melanoma, Neuroendocrine, and Solid Tumors at ASCO 2026 - Minichart
Perspective Therapeutics Showcases Strong Interim Radiopharma Data - TipRanks
Perspective Therapeutics (NYSE: CATX) highlights new 212Pb trial data at 2026 ASCO - Stock Titan
Perspective Therapeutics, Inc. Reports Positive Updates on Clinical Programs at ASCO 2026, Highlighting Efficacy and Safety of [212Pb]VMT-α-NET, [212Pb]VMT01, and [212Pb]PSV359 - Quiver Quantitative
Early melanoma trial sees tumor responses in hard-to-treat patients - Stock Titan
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation - MSN
Earnings Preview: CATX to Report Financial Results Post-market on May 11 - Moomoo
CATX: VMT-α-NET shows high efficacy and safety, with phase III readiness and broad pipeline progress - TradingView
CATX News | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Perspective Therapeutics doses first patients in two trial cohorts By Investing.com - Investing.com Australia
Perspective Therapeutics doses first patients in two trial cohorts - Investing.com UK
Perspective Therapeutics (CATX) Begins Patient Dosing in New Cli - GuruFocus
Perspective Therapeutics Doses First Patients for New Cohorts of Two Phase 1/2a Studies in Tumors - marketscreener.com
Perspective Therapeutics, Inc. Initiates Patient Dosing in Phase 1/2a Studies for [212Pb]VMT-α-NET and [212Pb]PSV359 in Neuroendocrine and Solid Tumors - Quiver Quantitative
Two cancer radiopharmaceuticals start dosing patients in early trials - Stock Titan
LifeSci Capital Remains a Buy on Perspective Therapeutics (CATX) - The Globe and Mail
CATX Should I Buy - Intellectia AI
Analysts Are Bullish on These Healthcare Stocks: SI-Bone (SIBN), Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
Morgan Stanley lists shared 2.6% stake in Perspective Therapeutics (CATX) - Stock Titan
RBC Capital reiterates Outperform on Perspective Therapeutics stock By Investing.com - Investing.com Nigeria
RBC Capital reiterates Outperform on Perspective Therapeutics stock - Investing.com
1.21%
1.43%
Capitalizzazione:
|
Volume (24 ore):